

**CinnaGen
at a Glance**

CinnaGen Group



Facility

- 15 Manufacturing plants
- 128,000 m² Working Area
- 24,500 m² Clean Room
- +40,000 liter bioreactor capacity
- ISO and EU cGMP Compatible





EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Europe



Iran



STATE SERVICE
OF UKRAINE ON MEDICINES
AND DRUGS CONTROL

Ukraine



Analitik Ekspertiza Mərkəzi

Azerbaijan



Philippines



Thailand




Malaysia



Sri Lanka



Colombia



Brazil



Turkey



Oman



Kenya



Comisión Federal para la Protección
contra Riesgos Sanitarios

Mexico



Uganda

GMP Approvals
Good Manufacturing Practice

Development of Manufacturing Process



Our People

33 years
Average Workforce age

+4,500 employees



CinnaGen Group in Numbers



+35 Biosimilars
commercialized

+15 Biosimilars
in pipeline


+90 Generics
commercialized

+30 Generics
in pipeline





more than **\$18B** Budget Saving in a Decade



4.5
Billion USD

Saving in 2024

With CinnaGen medications entrance
to the market



+1,000,000
Patients treated in 2024



**Each one a life touched
Each one, our purpose**

+200 Applications
in **36 Countries**



+250 Marketing
Authorizations in
38 countries



Exporting to
+40 countries

Our Global Impact

Exporting to

+40

countries





Accounting for

+60%

of Total

Pharmaceutical Export in Iran

8 Technology Transfer projects



Beyond Biosimilars, Embracing Social Responsibility





Our Ambition is Beyond Imagination